-
公开(公告)号：US20230355756A1
公开(公告)日：2023-11-09
申请号：US18245533
申请日：2021-08-06
发明人： Robin Barbour , Gene Kinney , Wagner Zago
IPC分类号： A61P37/04 , A61K39/395
CPC分类号： A61K39/3955 , A61P37/04 , A61K2039/6037
摘要： The disclosure provides peptide compositions and immunotherapy compositions comprising alpha-synuclein peptide. The disclosure also provides methods of treating or effecting prophylaxis of neurodegenerative diseases, such as Parkinson’s disease, dementia with Lewy bodies (DLB), Alzheimer’s disease or other synucleinopathies, with alpha-synuclein deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of alpha-synuclein, blocking the uptake by neurons and inhibiting propagation of alpha-synuclein seeds in a subject having or at risk of developing a neurodegenerative disease containing alpha-synuclein accumulations. The methods include administering to such patients the compositions comprising alpha-synuclein peptide.
-
公开(公告)号：US10889638B2
公开(公告)日：2021-01-12
申请号：US16091060
申请日：2017-05-02
摘要： The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
-
公开(公告)号：US10889636B2
公开(公告)日：2021-01-12
申请号：US15918937
申请日：2018-03-12
发明人： Stephen Jed Tam , Yue Liu , Robin Barbour , Theodore Yednock , Kenneth Flanagan
IPC分类号： A61K47/68 , C07K16/18 , G01N33/574 , A61K39/00
摘要： The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin α4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.
-
公开(公告)号：US10852309B2
公开(公告)日：2020-12-01
申请号：US15247598
申请日：2016-08-25
发明人： Robin Barbour , Lynn R. Zieske , Sarah Hamren
IPC分类号： G01N33/68 , C07K16/18 , G01N33/50 , G01N33/58 , G01N33/543
摘要： The invention provides methods of detecting alpha-synuclein using a capture antibody and a reporter antibody. The capture antibody binds preferentially to full-length alpha-synuclein phosphorylated at residue 129 (PS129 alpha-synuclein) over unphosphorylated full-length alpha-synuclein. The 11A5 antibody is an example of a suitable capture antibody. The reporter antibody binds to an epitope within residues 40-55 of alpha-synuclein. The 23E8 antibody is an example of such an antibody. Because only a small proportion of alpha-synuclein is phosphorylated high sensitivity of detection below picomolar is advantageous.
-
公开(公告)号：US10669331B2
公开(公告)日：2020-06-02
申请号：US16385968
申请日：2019-04-16
摘要： The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of α-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with α-synuclein, particularly accumulation of α-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).
-
公开(公告)号：US20190315843A1
公开(公告)日：2019-10-17
申请号：US16385968
申请日：2019-04-16
摘要： The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of α-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with α-synuclein, particularly accumulation of α-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).
-
公开(公告)号：US20170158755A1
公开(公告)日：2017-06-08
申请号：US15125569
申请日：2015-03-12
发明人： Kenneth Flanagan , Stephen Jed Tam , Yue Liu , Theodore Yednock , Robin Barbour
IPC分类号： C07K16/18
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/14 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/76 , C07K2317/92
摘要： The invention provides antibodies that specifically bind to the LG1-3 modules of the G domain of laminin α4. The antibodies have the capacity to inhibit binding of laminin α4 to MCAM. The antibodies can be used for inhibiting undesired immune responses, treatment of cancer, or treatment of obesity or obesity-related diseases, among other applications.
-
公开(公告)号：US20240209073A1
公开(公告)日：2024-06-27
申请号：US18422712
申请日：2024-01-25
发明人： Tarlochan S. Nijjar , Robin Barbour , Philip James Dolan, III , Yue Liu , Svetlana Alexander , Mark E. Renz
CPC分类号： C07K16/18 , C12N15/63 , A61K9/0019 , A61K45/06 , C07K2317/565
摘要： The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
-
公开(公告)号：US20230340094A1
公开(公告)日：2023-10-26
申请号：US18305109
申请日：2023-04-21
发明人： Peter Seubert , Philip James Dolan, III , Yue Liu , Robin Barbour
CPC分类号： C07K16/18 , A61K47/6843 , A61K47/6803 , A61P25/28 , A61K39/0007 , G01N33/6896 , C07K2317/24 , C07K2317/92 , A61K2039/505 , A61K2039/55 , C07K2317/34 , C07K2317/55 , G01N2333/47 , G01N2800/2821
摘要： The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
-
公开(公告)号：US20230126858A1
公开(公告)日：2023-04-27
申请号：US17937109
申请日：2022-09-30
发明人： Peter Seubert , Philip James Dolan, III , Yue Liu , Robin Barbour
摘要： The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
-
-
-
-
-
-
-
-
-
搜索结果
41 条记录 (耗时 0.026 秒)
